Context Therapeutics Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
CNTX Nasdaq 2834 www.contexttherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Context Therapeutics Inc.

Here's Why We're Not Too Worried About Context Therapeutics' (NASDAQ:CNTX) Cash Burn Situation - Feb 5th, 2026 9:06 am
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 16th, 2026 2:05 pm
BioAtla Inc (BCAB) Q3 2025 Earnings Call Highlights: Strategic Partnerships and Promising Trial ... - Nov 13th, 2025 10:04 pm
BioAtla Reports Third Quarter 2025 Financial Results and Highlights Recent Progress - Nov 13th, 2025 2:05 pm
Context Therapeutics Highlights CT-95 and CT-202 Programs at 2025 SITC Annual Meeting - Nov 7th, 2025 5:30 am
Context Therapeutics Reports Third Quarter 2025 Operating and Financial Results - Nov 5th, 2025 2:15 pm
Context Therapeutics to Participate in Upcoming Investor Conferences - Oct 28th, 2025 5:30 am
Institutions profited after Context Therapeutics Inc.'s (NASDAQ:CNTX) market cap rose US$14m last week but private equity firms profited the most - Oct 8th, 2025 4:48 am
Context Therapeutics Announces Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting - Oct 6th, 2025 5:30 am
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Oct 3rd, 2025 2:15 pm
Is Context Therapeutics (NASDAQ:CNTX) In A Good Position To Invest In Growth? - Aug 29th, 2025 9:02 am
Context Therapeutics Reports Second Quarter 2025 Operating and Financial Results - Aug 6th, 2025 2:11 pm
Context Therapeutics Presents CTIM-76 Phase 1 Trial in Progress at ASCO 2025 - Jul 25th, 2025 10:22 am
Co-Founder of Context Therapeutics Martin Lehr Buys 10% More Shares - Jun 11th, 2025 6:44 am
Context Therapeutics Announces CTIM-76 Trial in Progress Poster Presentation at 2025 ASCO Meeting - Jun 2nd, 2025 5:30 am
Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical Officer - May 29th, 2025 5:30 am
Context Therapeutics Reports First Quarter 2025 Operating and Financial Results - May 7th, 2025 2:09 pm
Context Therapeutics Announces Chief Medical Officer Transition - May 5th, 2025 2:05 pm
Context Therapeutics Presents Preclinical and Translational Data for CT-95, a Mesothelin Targeting T Cell Engager, at 2025 AACR Annual Meeting - Apr 30th, 2025 5:30 am
Context Therapeutics Doses First Patient in Phase 1 Clinical Trial of CT-95 - Apr 9th, 2025 5:30 am